Drug profile · INN
deutetrabenazine
AUSTEDO
deutetrabenazine (AUSTEDO) is a synaptic vesicular amine transporter inhibitor. Associated with Teva Pharma GmbH. Route of administration: oral. Current US regulatory status: approved.
Drug details — deutetrabenazine
- US status
- approved
- Class
- Nervous system (N07)
- Route
- ORAL
- Patents
- 0
- Programs
- 4
- Data quality
- 0.89
Quick answer
deutetrabenazine (AUSTEDO) is a synaptic vesicular amine transporter inhibitor. Associated with Teva Pharma GmbH. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Synaptic vesicular amine transporter inhibitor
Primary target: Synaptic vesicular amine transporter
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| EMA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is deutetrabenazine?
deutetrabenazine (AUSTEDO) is a synaptic vesicular amine transporter inhibitor. Associated with Teva Pharma GmbH. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for deutetrabenazine?
AUSTEDO is a marketed brand name for deutetrabenazine. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of deutetrabenazine?
deutetrabenazine has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.